Skip to main content
. Author manuscript; available in PMC: 2018 Aug 17.
Published in final edited form as: Clin Cancer Res. 2017 Sep 19;23(24):7454–7466. doi: 10.1158/1078-0432.CCR-17-0983

Figure 2.

Figure 2

Observed brain tumor pharmacokinetics of AZD1775 in 20 patients with glioblastoma following a single oral dose (100, 200, or 400 mg). A, Total AZD1775 tumor concentrations. B, Unbound AZD1775 tumor concentrations. C, Total AZD1775 tumor-to-plasma concentration ratios. D, Unbound AZD1775 tumor-to-plasma concentration ratios. Symbols represent observed data from individual patients, and lines represent median values.